Clinical trials: HIV Infected Individuals
NAFLD, NASH - Nonalcoholic Steatohepatitis
Vitamin E for NASH Treatment in HIV Infected Individuals
The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study is to learn if underlying liver condition…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
- Trial name
- NCT03669133
- Testing
- Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
HIV
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect…
- Trial name
- NCT01003990
- Testing
- Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine
- Where
- 88 sites in United States, Argentina and 23 more
- Volunteers
- 710 people
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
A Study of the Safety and Antiretroviral Activity of 3BNC117
This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of…
- Trial name
- NCT02588586
- Testing
- 3BNC117, Antiretroviral Treatment Interruption
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Rockefeller University
HIV Infection
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals.
- Trial name
- NCT01262846
- Testing
- Fluzone®
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- University of Pennsylvania
HIV Infections
iHIVARNA Clinical Trial in HIV Infected Individuals
iHIVARNA-01 is a novel therapeutic vaccine for the treatment of HIV-1-infected patients based on in vivo modification of DCs. It consists of HIVACAT-TriMix: mRNA encoding a mixture of APC activation molecules (CD40L, a…
- Trial name
- iHIVARNA-01 (NCT02888756)
- Testing
- iHIVARNA-01, TriMix
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 33 people
- Sponsor
- Rob Gruters
HIV Infections
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
This program is designed to study the efficacy, safety, lipid effects and tolerability of raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not received prior antiretroviral therapy.
- Trial name
- NCT00632970
- Testing
- Raltegravir, Lopinavir/Ritonavir, Truvada
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- George Washington University
HIV
Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals
The primary aim of this study is to determine the effects of the HIV integrase inhibitor, raltegravir, in cerebrospinal fluid (CSF).
- Trial name
- NCT01293123
- Testing
- Raltegravir, Efavirenz
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Diego
HIV Dementia
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Activated monocytes play a key role in the pathogenesis of HIV-associated neurocognitive disorders (HAND). Individuals with HAND have expanded populations of activated monocytes.
- Trial name
- NCT01263938
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
HIV, Metabolic Syndrome
Incidence of HANA Conditions in HIV-infected Individuals
With the availability of effective anti-retroviral therapy, HIV-infected individuals are expected not to die of AIDS and have longer life expectancy.
- Conditions
- HIV, Metabolic Syndrome, Osteopenia, Osteoporosis
- Trial name
- NCT03483584
- Where
- Hong Kong
- Volunteers
- 215 people
- Sponsor
- Chinese University of Hong Kong
HIV Infections, Herpes Genitalis
Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda
This study will determine whether acyclovir, a medicine used to treat herpes simplex virus 2 (HSV-2), can slow down the progression (worsening) of HIV disease in people with both HIV and HSV-2 infections.
- Trial name
- NCT00405821
- Testing
- Acyclovir
- Where
- Uganda
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
This multicenter, international, non randomized (single arm), open, phase II trial aims to evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological success in virologically suppressed HIV-1…
- Trial name
- NCT02212379
- Testing
- raltegravir and etravirine
- Where
- 19 sites in France, Spain
- Volunteers
- 170 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Human Immunodeficiency Virus
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at…
- Trial name
- NCT04250636
- Testing
- 3BNC117-LS, 10-1074-LS
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Rockefeller University
Cryptococcal Meningitis, HIV Infections
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal meningitis (CM) is an infection of the membranes covering the brain and spinal cord, caused by the fungus Cryptococcus neoformans.
- Trial name
- NCT00885703
- Testing
- Fluconazole, Amphotericin B
- Where
- 10 sites in United States, India and 6 more
- Volunteers
- 168 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Efficacy of Neuro-HAART in Patients With HIV
Patients infected with Human Immunodeficiency Virus (HIV) are at risk of brain related complications despite the use of highly active antiretroviral therapy (HAART).
- Trial name
- HANDobs (NCT01434654)
- Where
- 2 sites in Australia
- Volunteers
- 19 people
- Sponsor
- St Vincent's Hospital, Sydney
HIV
Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Background: Human immunodeficiency virus (HIV) affects the immune system. The main function of the immune system is protect you from infections and other diseases such as cancer.
- Trial name
- NCT03571204
- Testing
- 3BNC117 and 10-1074
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
This study will examine whether intensification with raltegravir of a suppressive antiretroviral regimen in HIV infected patients with poor immune restoration has a beneficial effect on cryptic viral replication and the immune…
- Trial name
- NCT01245101
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Miami
HIV-1 Infection
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
The purpose of this study is to determine whether a two-week course of disulfiram will reduce the HIV-1 latent reservoir in patients on highly active antiretroviral therapy (HAART).
- Trial name
- NCT01286259
- Testing
- Disulfiram
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV/AIDS, Hypertension
Systems Analysis and Improvement Approach for the Hypertension Care Cascade
As undiagnosed and untreated hypertension is one of the largest drivers of cardiovascular disease in sub-Saharan Africa approaches are needed to optimize the hypertension care cascade.
- Trial name
- SAIA-HTN (NCT04088656)
- Testing
- Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization
- Where
- 16 sites in Mozambique
- Volunteers
- 305 people
- Sponsor
- University of Washington
HIV Infection, LTBI
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
This study evaluated the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT was given with isoniazid (INH) daily for 4 weeks (1HP) as part of treatment for latent TB infection…
- Trial name
- NCT04272242
- Testing
- Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT)
- Where
- 10 sites in United States, Botswana and 5 more
- Volunteers
- 37 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
This study is a prospective, open-label, randomized, three-arm, dose-escalation exploratory pilot clinical trial involving HIV-1 infected participants treated with suppressive combination antiretroviral combination therapy…
- Trial name
- ACTIVATE (NCT02471430)
- Testing
- Panobinostat, Pegylated Interferon-alpha2a
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital